It’s been a historic week for Mile High Labs, a 400,000-square-foot pharmaceutical facility was reborn as the epicenter for their CBD manufacturing, distribution, testing and research.
Before the acquisition of the Broomfield facility, the company extracted CBD in a 1,500-square-foot lab in Loveland, Colorado. The opening of their new Broomfield facility marks a turning point for Mile High Labs as they continue to scale their operations and supply CBD to product manufacturers.
Legitimizing the CBD Industry
CBD deserves to be taken seriously, as do the people who grow it, make it and take it. Mile High recognize the responsibility they have as advocates for consumers, product manufacturers, cultivators and even their fellow extractors. That’s why all of their significant achievements this year have aimed to legitimize the CBD industry as a whole.
“I’m excited just about the scale and ambition of this place, and the way it changes how people think about the CBD industry and how people think about the company,” Stephen Mueller, CEO of Mile High Labs said.
In Good Company
The Governor of Colorado, Jared Polis, and Mayor of Broomfield, Randy Ahrens, were in attendance at the opening of the facility. Governor Polis has been a longtime advocate for the hemp industry, and under his leadership, he’s supported countless farmers and innovators. Mayor Ahrens was kind enough to welcome Mile High Labs into the vibrant community of businesses that call Broomfield home.
Also in attendance were legislators from Mexico with whom Mile High Labs have been in talks about CBD regulation. Mexican lawmakers are poised to vote on cannabis legalization at the end of the month, and Mile High Labs have been working with them to provide insight on their experience with CBD in US and EU markets.
Ready for Regulation
With the opening of Mile High Labs' new headquarters, the stage is set for the CBD movement to reach its true potential. However, the impressive market value projections we see from organizations like Brightfield group are all based on the premise that the FDA will establish a framework for compliant CBD products by mid-to-late-2020
“There’s this limbo now where we’re investing a lot into the quality and compliance side, but it’s not really being recognized, the value of that. And the industry is being stifled because we don’t have big companies that can get involved,” Mueller said.
As they continue to ramp up production in Broomfield, Mile High Labs have one message to FDA and regulatory officials: act now. The longevity of the CBD industry and the well-being of CBD consumers around the world depend on it.
For more information:
Mile High Labs
1011 Walnut St. Suite 200
Boulder, Colorado 80302